TrueWealth Advisors’s iShares Biotechnology ETF IBB Stock Holding History

TrueWealth Advisors’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,751	Closed	-$420K	–	179
2022 Q1	$420K	Hold	2,751	–	–	0.19%	103
2021 Q4	$420K	Buy	2,751 +198	+8%	+$30.7K	0.19%	103
2021 Q3	$413K	Buy	+2,553	New	+$430K	0.23%	81

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

TrueWealth Advisors's IBB Position: Q2 2022 in Review

TrueWealth Advisors sold out of iShares Biotechnology ETF (IBB) in Q2 2022, closing a stake of 2,751 shares — an estimated $420K sold.

TrueWealth Advisors first reported a position in IBB in Q3 2021 and held it in 3 quarters. The position peaked at $420K in Q1 2022. 858 funds tracked by Wall St. Rank hold IBB as of Q2 2022.

TrueWealth Advisors reported no remaining iShares Biotechnology ETF position as of Q2 2022 after selling out during the quarter.
TrueWealth Advisors sold 2,751 iShares Biotechnology ETF shares in Q2 2022, an estimated $420K.
TrueWealth Advisors first reported a position in iShares Biotechnology ETF in Q3 2021 and held it in 3 quarters.
TrueWealth Advisors's iShares Biotechnology ETF position peaked at $420K in Q1 2022.
858 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2022.

Based on TrueWealth Advisors's 13F filing for Q2 2022, filed 27 Jul 2022.